Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3)

Dennis Turk, Ph.D.

Committee: Arthritis Drugs Advisory Committee

Meeting Date: November 29, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the committee's discussions of the safety and efficacy of New Drug Application NDA 20-998, supplement 021, trade name, Celebrex (celecoxib), a non-steroidal anti-inflammatory drug (COX-2 inhibitor), manufactured by Searle Ltd. for G.D. Searle LLC, subsidiaries of Pfizer, for the proposed indication of the relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) in patients two years and older. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	**Nature**	**Magnitude**
Unrelated Advisory Board	Competing Firm	Less than $10,001 per year
Unrelated Consulting	Competing Firm	Less than $10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

_____/S/_____ October 17, 2006_
Signature of SGE Date